Low detectable prostate specific antigen after radical prostatectomy--treat or watch?

[1]  Jean M. Mitchell.  Urologists' use of intensity-modulated radiation therapy for prostate cancer. , 2013, The New England journal of medicine.

[2]  S. Goldenberg,et al.  Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. , 2013, The Journal of urology.

[3]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[4]  R. Thompson,et al.  Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. , 2012, The Journal of urology.

[5]  Charles A Enke,et al.  Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Markus Graefen,et al.  Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. , 2012, European urology.

[7]  A. Dicker,et al.  Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. , 2012, European journal of cancer.

[8]  M. Sydes,et al.  Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense?: in regard to King CR (Int J Radiat Oncol Biol Phys 2011;80:1-3). , 2011, International journal of radiation oncology, biology, physics.

[9]  Judith D Goldberg,et al.  Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. , 2011, European urology.

[10]  R. Thompson,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[11]  C. King.  Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense? , 2011, International journal of radiation oncology, biology, physics.

[12]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[14]  S. Joniau,et al.  Re: Bianco FJ, Scardino PT, and Eastham JA: Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("Trifecta") (Urology 66(5 suppl): 83-94, 2005). , 2008, Urology.

[15]  R. Millikan,et al.  Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen level , 2007, Cancer.

[16]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[17]  A. Partin,et al.  Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. , 2006, The Journal of urology.

[18]  M. Menon,et al.  Robotic radical prostatectomy with the "Veil of Aphrodite" technique: histologic evidence of enhanced nerve sparing. , 2006, European urology.

[19]  P. Scardino,et al.  Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). , 2005, Urology.

[20]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[21]  Samir S Taneja,et al.  Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. , 2005, The Journal of urology.

[22]  H. Lilja,et al.  Expression of prostate‐specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues , 2005, International journal of cancer.

[23]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[24]  J. Brooks,et al.  Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen. , 2003, Urology.

[25]  E. Bergstralh,et al.  Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? , 2001, The Journal of urology.

[26]  M. Rubin,et al.  Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. , 2000, Urology.

[27]  E. Klein,et al.  Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. , 1999, Urology.

[28]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[29]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[30]  J. Melamed,et al.  The role of bladder neck biopsy in men undergoing radical retropubic prostatectomy with preservation of the bladder neck. , 1998, The Journal of urology.

[31]  Ján.  Treatment failure after primary and salvage therapy for prostate cancer : likelihood , patterns of care , and outcomes , 2014 .

[32]  R. Ackermann.  Postoperative Radiotherapy After Radical Prostatectomy: A Randomised Controlled Trial (EORTC trial 22911) , 2006 .

[33]  D. Lubeck,et al.  Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. , 2004, The Journal of urology.

[34]  L. Baert,et al.  Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. , 1996, The Journal of urology.